Charge heterogeneity in monoclonal antibodies can negatively impact binding affinity and potency, so it is critical to ensure that individual charge variants of biotherapeutic molecules are thoroughly characterized to ensure product quality. Dr. Chris Heger (Bio-Techne) and Dr. Mike Piazza (Nicoya Lifesciences) will illustrate a fast, simple icIEF fractionation and digital SPR workflow that provides in-depth characterization of the charge variants of a therapeutic bispecific antibody (BsAb) Mosunetuzumab and a research-grade biosimilar. Using a combination of the MauriceFlex™ system and Alto™ Digital SPR, they demonstrate a novel method that utilizes imaged capillary isoelectric focusing (icIEF)-based charge separation and fractionation followed by binding affinity analysis using surface plasmon resonance, offering a robust and efficient approach to evaluating charge variants. Prior LC-MS analysis of the fractions uncovered interesting differences between the two molecules. The speakers will show how the high-purity fractions of both the innovator drug and a research-grade biosimilar were analyzed by SPR for binding studies with their ligands CD3 and CD20, revealing notable differences in binding affinity, particularly between the biosimilar’s acidic peak and ligand CD20.
Useful resources are linked below.
As the world’s only surface plasmon resonance (SPR) system powered by digital microfluidics, Alto™ revolutionizes real-time interaction analysis by eliminating the need to compromise on quality and time. Go from sample to answer within hours while streamlining even the toughest of biologics applications with Alto’s intuitive and automated ecosystem. Designed to take the complexity out of SPR, Alto™ will empower your team with the data they need to take their discoveries to the next level.
Read it here.
Alto’s comprehensive software, the Nicosystem, provides a one-stop centralized hub for acquisition and analysis of real-time binding data, all while offering an intuitive user interface, one-click analysis feature, and the flexibility of accessing your experiments from anywhere.
Learn more here.
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
Â
"*" indicates required fields
Â
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
Over 600 researchers worldwide are using OpenSPRâ„¢ to get the data reviewers are looking for. Read our brochure to learn more!
"*" indicates required fields
Interested in learning more about how Alto can accelerate your drug discovery? Fill out the form below to download a product brochure.
"*" indicates required fields